Symposium | Customizing therapy for MCL: Q&A

During the 18th International Conference on Malignant Lymphoma (ICML), June 17–21, 2025, Lugano, CH, the Lymphoma Hub held a symposium on June 17, 2025, titled Customizing therapy for mantle cell lymphoma (MCL). 

The symposium concluded with a panel Q&A session that included live audience participation. The panelists, Gilles Salles, Julie Vose, Wojciech Jurczak, and Michael Wang, shared their perspectives on:

• How to manage patients with central nervous system involvement.

• The role of hematopoietic stem cell transplantation in patients with MCL.

• The impact of TP53 mutation on treatment decisions.

• Optimal duration of treatment with Bruton’s tyrosine kinase inhibitors (BTKi).

• The role of radiation therapy in patients with MCL.

• The use of covalent BTKi in earlier lines of therapy, and the optimal sequencing of therapies.

This educational resource is independently supported by Eli Lilly and Company. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.